Pharm

Entry Inhibitor

search

Entry Inhibitor, Maraviroc, Selzentry

  • See Also
  1. Anti-Retroviral Therapy
  • Class
  1. Anti-retroviral agent
  2. Entry Inhibitor
  • Mechanism
  1. Blocks HIV to Chemokine (CCR5 - R5) receptor binding on CD4+ Cells
  2. Since only effective on R5 cells - requires R5 tropism test prior to initiating Maraviroc
  • Indications
  1. Anti-retroviral naive patients
  2. Anti-retroviral experienced patients
  • Adverse Effects
  1. Well tolerated overall
  2. Fever
  3. Upper respiratory symptoms (e.g. cough, Bronchitis)
  4. Abdominal Pain
  5. Rash
  6. Orthostatic Hypotension
  7. Myalgia
  8. Hepatotoxicity (may be associated with rash and Eosinophilia)
  9. Increased Myocardial Infarction risk
  • Monitoring
  1. Requires R5 tropism test prior to initiating Maraviroc
  • References
  1. (2009) Treat Guidel Med Lett 7(78): 11-22 [PubMed]
  2. Reust (2011) Am Fam Physician 83(12): 1443-51 [PubMed]